江苏扬中市2013年儿童及老人流感抗体水平分析  

Influenza antibody levels in children and old peoples in Yangzhong City,Jiangsu Province,China in 2013

作　　者：储艳[1] 朱蓓蓓[1] 柴文清[1] 陈丹丹[1] 马福宝[2] 沈炜[1] 

机构地区：[1]上海生物制品研究所有限责任公司,上海200052 [2]江苏省疾病预防控制中心,江苏南京210009

出　　处：《中国生物制品学杂志》2016年第5期511-513,518,共4页Chinese Journal of Biologicals

摘　　要：目的分析江苏扬中市儿童及老人的流感流行状况,为预防疾病和制定免疫策略提供依据。方法按照整群分层随机抽样的原则,于2013年9月采集扬中市下辖6个乡镇1 449名健康儿童及老人的静脉血,分离血清,采用微量血凝抑制(hemagglutination inhibition,HI)试验检测血清抗体。结果共采集血清1 449份,其中儿童组739份,老人组710份。H1N1、H3N2和B型3个型别抗体阳性率均在70%以上,抗体保护率分别为44.10%、31.88%和65.98%,抗体几何平均滴度(geometric mean titer,GMT)分别为1∶26.19、1∶18.00和1∶48.76。其中儿童组H1N1型抗体保护率达62.38%,抗体GMT为1∶41.48。结论 B型在儿童和老人中流行较广泛,是该部分人群的流感流行优势毒株。H1N1型在儿童中发生过流行,并已产生了相应抗体。在流感高发季节,对儿童及老人等重点人群进行流感疫苗的预防接种是必要的。Objective To analyze the epidemic of influenza in children and old peoples in Yangzhong City,Jiangsu Province,China,and provide a basis for prevention of the disease and development of immune strategy.Methods Stratified group and random sampling were adopted.A total of 1 449 serum samples were collected from healthy children and old peoples in six townships in Yangzhong City in September 2013,and determined for antibody by micro-hemagglutination inhibition（HI）test.Results A total of 1 449 serum samples were collected,of which 739 were from children,and 710 from old peoples.All the positive rates of antibodies of types H1N1,H3N2 and B were more than 70%,while the antibody protective rates were 44.10%,31.88% and 65.98%,and GMTs were 1 ∶ 26.19,1 ∶ 18.00 and 1 ∶ 48.76,respectively.The protective rate and GMT of antibody against type H1N1 in children were 62.38% and 1 ︰ 41.48 respectively.Conclusion Influenza type B was popular in children and old peoples,which was the dominant strain among these crowds.However,the epidemic of influenza type H1N1 occurred in children in the past and induced the corresponding antibody.In the seasons with high occurrence of influenza,it is necessary to inoculate influenza vaccine in focus crowds such as children and old peoples.

关 键 词：流感病毒 抗体水平 

分 类 号：R373.13[医药卫生—病原生物学] R181.36[医药卫生—基础医学]